EyePoint Pharmaceuticals

Press Releases

EyePoint Pharmaceuticals Announces New Agreement for Expanded Access of DEXYCU® Within One of the Largest Integrated Delivery Systems in the U.S.
Dec 04, 2019
WATERTOWN, Mass. , Dec. 04, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Company has entered into a formal two-year contract with
EyePoint Pharmaceuticals Announces Amendment to CRG Debt Facility
Nov 19, 2019
WATERTOWN, Mass. , Nov. 19, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced an amendment to its existing debt facility with CRG Servicing LLC
EyePoint Pharmaceuticals Appoints George O. Elston as Chief Financial Officer and Head of Corporate Development
Nov 14, 2019
Veteran biopharmaceutical executive with broad experience at global companies brings more than 25 years of finance, partnering and M&A experience to role WATERTOWN, Mass. , Nov. 14, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company
EyePoint Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate Progress
Nov 07, 2019
– U.S. commercial launch trajectory for DEXYCU® and YUTIQ® gains momentum with strong customer order growth over Q2 – – DEXYCU customer orders increased 207% over Q2 with repeat customers representing 74% of order volume – – YUTIQ customer orders up 17% over Q2 with repeat customers representing
EyePoint Pharmaceuticals Announces Addition of DEXYCU® and YUTIQ® to Department of Veteran Affairs Federal Supply Schedule
Nov 04, 2019
- DEXYCU and YUTIQ now available across the VA and on Federal Supply Schedule to benefit U.S. veterans and other government employees - WATERTOWN, Mass. , Nov. 04, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing
EyePoint Pharmaceuticals Secures New Patient Access Agreement with Vizient Inc. for DEXYCU®
Nov 01, 2019
DEXYCU to be available to diverse member network of Vizient, the largest GPO in the U.S. WATERTOWN, Mass. , Nov. 01, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic
EyePoint Pharmaceuticals Announces Third Quarter 2019 Financial Results Release Date and Conference Call Information
Oct 24, 2019
WATERTOWN, Mass. , Oct. 24, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its third quarter ended September 30, 2019 on Thursday,
EyePoint Pharmaceuticals Announces Permanent and Specific J-Code for YUTIQ® Now in Effect
Oct 02, 2019
WATERTOWN, Mass. , Oct. 02, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, announced today that the Company’s permanent and specific J-Code for YUTIQ®
EyePoint Pharmaceuticals Announces YUTIQ® Presentations at the American Academy of Ophthalmology 2019 Annual Meeting
Sep 27, 2019
WATERTOWN, Mass. , Sept. 27, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that two abstracts supporting the Company's YUTIQ ® (fluocinolone
EyePoint Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference
Sep 26, 2019
WATERTOWN, Mass. , Sept. 26, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Nancy Lurker, President and Chief Executive Officer, is
EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ® to be Presented at the 52nd Annual Retina Society Scientific Meeting
Sep 09, 2019
WATERTOWN, Mass. , Sept. 09, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that two abstracts supporting the Company's YUTIQ® (fluocinolone
EyePoint Pharmaceuticals Reports Second Quarter 2019 Financial Results and Highlights Recent Company Progress
Aug 07, 2019
– Company reports total revenue of $7.2 million – – Two commercial product launches in U.S. are underway for DEXYCU ® and YUTIQ ® with 43 sales reps actively targeting uveitis specialists, cataract surgeons and ambulatory surgical centers – – YUTIQ receives specific and permanent J Code, effective
EyePoint Pharmaceuticals Presents Positive Data Showcasing YUTIQ® at the 37th Annual Scientific Meeting of the American Society of Retina Specialists
Jul 30, 2019
WATERTOWN, Mass. , July 30, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the presentation of data supporting the Company's YUTIQ ®
EyePoint Pharmaceuticals Announces Early Assignment of Permanent and Specific J-Code J7314 for YUTIQ® by the Center for Medicare and Medicaid Services (CMS)
Jul 25, 2019
WATERTOWN, Mass. , July 25, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Centers for Medicare and Medicaid Services (CMS) has
EyePoint Pharmaceuticals Announces Second Quarter 2019 Financial Results Release Date and Conference Call Information
Jul 24, 2019
WATERTOWN, Mass. , July 24, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its second quarter ended June 30, 2019 on Wednesday, August 7
EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ® to be Presented at the 37th Annual Scientific Meeting of the American Society of Retina Specialists
Jul 23, 2019
WATERTOWN, Mass. , July 23, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that three abstracts supporting the Company's YUTIQ ® (fluocinolone
EyePoint Pharmaceuticals Appoints Wendy DiCicco, CPA, to Board of Directors
Jul 15, 2019
Ms. DiCicco is a Veteran Healthcare Executive with 30 Years of Financial and Corporate Development Experience WATERTOWN, Mass. , July 15, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing
EyePoint Pharmaceuticals Added to Russell 3000® and 2000® Indexes
Jul 01, 2019
WATERTOWN, Mass. , July 01, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) (“Eyepoint”), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Company has joined the broad-market Russell
EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 13, 2019
WATERTOWN, Mass. , June 13, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today reported the grant of inducement awards to Scott Jones , EyePoint’s newly
EyePoint Pharmaceuticals Strengthens Executive Leadership Team with Key Hires
Jun 10, 2019
- Scott Jones Appointed as Chief Commercial Officer - - Said Saim, Ph.D., Appointed as Chief Technology Officer - WATERTOWN, Mass. , June 10, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing
Displaying 1 - 20 of 363
EyePoint Pharmaceuticals